Journal article
OR31-04 Efficacy and Safety of Veligrotug (VRDN-001), a Full Antagonist Monoclonal Antibody to IGF-1 Receptor, in Active Thyroid Eye Disease (TED): THRIVE Phase 3 Topline Results
Abstract
Abstract
Disclosure: R. Mudumbai: Viridian Therapeutics, Inc., Nicox Ophthalmics, Stoke Pharmaceuticals. S. Leibowitz: Viridian Therapeutics, Inc., Lassen Therapeutics LLC, Amgen. Y. Michael T.: Viridian Therapeutics, Inc., Ipsen Innovations, Sling Therapeutics. K. Cockerham: Viridian Therapeutics, Inc., Horizon Therapeutics, Immunovant, Lassen Therapeutics LLC, Tourmaline, Roche. J. Abrams: Viridian Therapeutics, Inc., Horizon Therapeutics. …
Authors
Mudumbai R; Leibowitz S; T. YM; Cockerham K; Abrams J; Turbin RE; Nijhawan N; Zhang-Nunes S; Kossler A; Michalsky C
Journal
Journal of the Endocrine Society, Vol. 9, No. Supplement_1,
Publisher
The Endocrine Society
Publication Date
October 22, 2025
DOI
10.1210/jendso/bvaf149.2237
ISSN
2472-1972